QH-104

Product Description

A preparation of a subset of allogeneic T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) targeting the immunoregulatory protein and tumor-associated antigen (TAA) B7-homologue 3 (B7-H3, CD276), with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-B7-H3 CAR gamma delta T cells QH104 target and bind to B7-H3-expressing tumor cells, thereby inducing selective toxicity in B7-H3-expressing tumor cells. Gamma delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-anti-b7-h3-car-gamma-delta-t-cells-qh104)

Mechanisms of Action: CAR-T,B7-H3

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None